Targovax has submitted a study protocol to the regulatory authorities in Spain to assess its ONCOS-102 product in combination with chemotherapy in patients with malignant pleural mesothelioma , a rare type of lung cancer associated with exposure to asbestos. “This submission marks another important step for Targovax, delivering on our strategy to initiate trials to study the ONCOS-102 platform in multiple indications” says Gunnar Gardemyr, CEO of Targovax.
